I've lost 25% of my weight on Mounjaro – here's 4 foods I avoided on fat jabs & the popular pick that made me feel sick
FOOD FOR THOUGHT I've lost 25% of my weight on Mounjaro – here's 4 foods I avoided on fat jabs & the popular pick that made me feel sick
Click to share on X/Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
A WOMAN who's shed nearly 25% of her bodyweight thanks to Mounjaro has revealed which foods she steered clear of.
TikToker Tami kickstarted her weight loss journey with the popular fat jab almost a year ago and within the last 50 weeks she's managed to drop a staggering 1/4 of her starting weight.
Sign up for Scottish Sun
newsletter
Sign up
3
Tami kickstarted her weight loss journey with the popular fat jab almost a year ago
Credit: tiktok/@cartcrushuk
3
She has since managed to shed almost 25% of her body weight
Credit: tiktok/@cartcrushuk
3
Mounjaro is typically used to treat type 2 diabetes
Credit: Getty
Like many, Tami wasn't ''too clued up'' on what to do and which foods to consume.
However, having been on Mounjaro for close to 12 months now, Tami has learnt what works for her, regularly sharing tips and tricks to others on the same journey.
Mounjaro is regarded by some as the King Kong of weight loss jabs.
Sun GP Dr Zoe Williams acknowledged that Mounjaro, which could soon be rolled out on the NHS, can save the lives of people with 'life-threatening levels of obesity.'
But despite this, the NHS warned: 'Never take an anti-obesity medicine if it has not been prescribed to you.
"These types of medicines may not be safe for you and can cause serious side effects.'
About half a million Brits use weight loss drugs - and the number is expected to double in the next year.
Mounjaro works by suppressing your appetite, making people feel fuller for longer.
The injections are licensed for patients with type 2 diabetes and to assist those who are clinically obese (with a Body Mass Index of 30 or over).
One jab is administered each week but the duration is dependent on someone's weight.
I went on fat jabs but the hair loss was unbelievable so I quit - I'd rather be chubby with hair than skinny and bald
Spilling the beans on the popular foods she avoided, Tami revealed she didn't consume complex carbs, such as spaghetti and toast.
''Pasta and bread made me feel quite sick, I learnt that during the way,'' she said in the video.
''White breads and white pasta I found that it was very much making me feel queasy, so I avoided that.''
Another item on the no-go list included red meat, as that gave her ''the sulphur burp'', which ''have a foul, rotten egg smell due to the presence of hydrogen sulfide gas'', as per Medical News Today.
As well as being caused by gastrointestinal issues, sulphur burps can be a result of consuming too much legumes, dairy, poultry and other meat.
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
''I've now introduced it back into my diet but certainly in the beginning and when moving up doses,'' said Tami who's currently on 15mg of the medication.
Another popular pick she steered clear of at the start of her weight loss journey was takeaway, especially ''fatty and greasy foods''.
As well as making her stomach ''quite sick'', Tami discovered the greasy meals caused constipation - another common side effect of Mounjaro.
''Also, I would avoid anything high in sugar, sugary foods, like cakes.''
Offering a helping hand to those also on the medication, Tami advised to stay hydrated and ''eat your calories''.
She went on in the video: ''I would say that if you've got any questions regarding foods or something's triggering you, write it down in a food diary.
''See what could made you feel sickly and probably take it out of your eating plan for that week and see if that's the trigger.''
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
Other Mounjaro users react
Since being posted on the platform, where Tami shares content under the username @cartcrushuk, the clip has taken the internet by storm, amassing over 368k views.
More than 400 people flooded to comments, where many shared their experience with the fat jab.
One person said: ''I am completely gone off chicken like makes me wanna vom.''
Someone else chimed in: ''Same I find highly processed carbs give me a bad belly I just stick to fresh protein and veg now lost 4 stone upto now.''
Another wrote: ''Week 8 …32lb down..zero side effects…I eat in deficient I drink 2.5 litres of water with electrolytes now gone up to 5mg loving it!''
The reality of Mounjaro
Although many have boasted about weight loss success since using Mounjaro, last year it was revealed that Scots nurse Susan McGowan, 58, died after taking low-dose injections of Mounjaro over a fortnight.
A probe also found that nearly 400 people have gone to hospital after taking weight loss drugs.
The common side effects include nausea, vomiting and diarrhoea, which can lead to severe dehydration.
And if that wasn't bad enough, doctors say they have also seen 'life-threatening complications', including seizures, bowel obstruction and inflammation of the pancreas.
Model Lottie Moss, 27, even said she had a seizure after taking high doses of Ozempic.
The makers of Mounjaro, Lilly UK, said patient safety is its 'top priority'.
Lilly UK stressed: 'Regulatory agencies conduct extensive independent assessments of the benefits and risks of every new medicine and Lilly is committed to continually monitoring, evaluating, and reporting safety data.
'If anyone is experiencing side effects when taking any Lilly medicine, they should talk to their doctor or other healthcare professional.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
2 minutes ago
- The Independent
Thousands of patients miss out on weight loss jab due to NHS ‘postcode lottery'
Thousands of obese patients are missing out on a key weight loss jab due to a 'postcode lottery' of provision in the NHS, according to a report. Mounjaro, dubbed the 'King Kong' of weight loss medicine, was supposed to be available through GP surgeries from 23 June under an agreement between NHS England and NICE. But just eight out of 42 NHS Integrated Care Boards (ICBs) in England were able to provide treatment to patients, according to Sky News, who obtained the data using a Freedom of Information request. Many other ICBs were reportedly unable to confirm when treatment would be available. Dr Jonathan Hazlehurst, an endocrinologist and obesity physician at University Hospitals Birmingham, said patients were 'set up for failure' and have been treated unfairly. "Giving people open promises and setting them up for disappointment and failure is clearly grossly unfair. That's what the current system is doing,' he told the broadcaster. NICE said in December that the NHS should offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. It calculated from NHS England data that there were 97,500 patients who should be treated in the first year. But Dr Hazlehurst claims NHS England has only provided funding for just over 22,000 patients. The Independent has approached NHS England for comment. A spokesperson told Sky News that NHS England had "fully supported the rollout" of Mounjaro. "We issued guidance and provided funding in March to all Integrated Care Boards to support treatment costs, enable scaling of services and provide wrap-around care, including digital support services,' they said. It comes after NICE warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. The new 'quality standard' from NICE says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made.'
Daily Mail
33 minutes ago
- Daily Mail
Health officials tell UK to brace for surge of virus that is the leading cause of death in newborns
Britons have been warned to brace themselves for an upsurge in cases of a deadly lung infection amid a global rise. Respiratory syncytial virus (RSV), which can be deadly for young children and the elderly, flares up every autumn in the UK—just like the flu. But official surveillance data shows Australia has already logged a record number of cases this year. NHS chiefs believe the Australian winter is a good predictor of how viruses will spread in the UK. Spread by coughs and sneezes, it hospitalises around 30,000 children and 18,000 adults in the UK every year, due to serious breathing complications like pneumonia and lung infections. It said that the virus is a leading cause of death among babies. Around 20 to 30 children die from the virus each winter. It's also estimated to contribute to the deaths of 8,000 adults over the same period, due to the increased strain the infection puts on patient's hearts, causing the organ to fail. Officials have now urged pregnant women and those eligible to get the RSV vaccine. Kate Brintworth, chief midwifery officer for NHS England, said: 'While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation. 'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born. 'Now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.' Last week, data published by the UK Health Security Agency (UKHSA) also showed the jab for pregnant women can prevent almost three quarters (72 per cent) of hospital admissions for their babies. The antibodies the mums produce in response to the jab are passed to their babies in the womb, protecting them for the first six months after being born. Meanwhile, the vaccine is 82 per cent effective at preventing hospital admissions for RSV among older adults, the UKHSA noted. Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the jab and NHS England will start inviting people to come forward in the next few weeks. The NHS's jab rollout comes as part of its winter vaccine plans, which also includes Covid and flu vaccines. The lung condition spreads by large droplets and the virus can survive on surfaces for up to seven hours. Children remain infectious for up to three weeks, even after their symptoms have passed. Higher risk babies can receive the nirsevimab vaccine from September—with the single jab replacing five monthly injections previously given to infants classed as being at high risk.
Sky News
43 minutes ago
- Sky News
Ozempic to Mounjaro - what are the weight loss injections and what were they designed to do?
Drugs designed to treat diabetes and repurposed as miracle diet aids have taken over TikTok - and Hollywood. The weight loss caused by these weekly injectables is rapid and previously unattainable, people boast, showing off newly svelte bodies. But what are these drugs, how do they work - and what were they originally designed to do? Ozempic, Wegovy, Mounjaro - what are they? Let's start with the most well-known of the trio: Ozempic. Ozempic blew up in 2022 - if media reports from the US were to be believed, every pound dropped in LA was probably thanks to the "miracle" injectable drug. What started as the preserve of A-listers and the Hollywood elite quickly grew in popularity. The drug's generic name is semaglutide. This is the same as Wegovy, which has been licensed as a weight loss drug in the UK and is now available on the NHS. Wegovy has a slightly higher dosage and is designed for weight loss, while Ozempic's primary purpose was as a diabetes treatment (more on that later). Mounjaro - also known by its generic name tirzepatide - is the newer kid on the block. Like Ozempic and Wegovy, it suppresses the appetite and lengthens the amount of time food stays in the stomach, leading to weight loss - at least for as long as you carry on taking it. In 2022, the US Food and Drink Administration (FDA) fast-tracked approval of the drug to treat obesity after a study showed it helped people lose more than 20% of their bodyweight. Mounjaro was supposed to be available through GP surgeries and other community services in the UK from 23 June. But at the start of August, Sky News research revealed only eight of 42 NHS Integrated Care Boards (ICBs) in England had started providing treatment to patients, and many of the rest unable to guarantee when it would be available. 3:31 From diabetes drug to diet pill Ozempic and Mounjaro were both developed as treatments for type 2 diabetes. The drugs, which come as weekly injections, lower blood sugar by increasing insulin production when your blood sugar is rising and helping prevent your liver making and releasing too much sugar. So how do they cause weight loss? Both semaglutide and tirzepatide work by mimicking the hormone, GLP-1 (glucagon-like peptide one), to manage hunger and slow down digestion. Tirzepatide - Mounjaro - is a dual-acting drug and also mimics the hormone GIP (glucose-dependent insulinotropic polypeptide). In terms of weight loss, in clinical trials people lost up to 20% of their body weight on tirzepatide and 15% on semaglutide. Researchers have also found the weight loss jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose. They sound like miracle drugs for people wanting to lose weight - what's the catch? There are a few downsides. First off, the listed side effects: nausea, vomiting and diarrhoea, bad enough for about 5% of people in the semaglutide trial to stop taking it and 6-7% in the tirzepatide trial. People in the semaglutide trial also experienced problems with gallstones. The drugs also carry serious risks including kidney failure, pancreatitis and thyroid cancer. Another downside has been dubbed "Ozempic face". Facial ageing is a side effect of sudden weight loss as people find the skin on their face sagging where once it was plump. The drugs also only work for as long as you carry on taking them, and people have reported gaining back all the weight they lost after stopping the drug - either out of choice or because of a supply shortage. In August, the National Institute for Health and Care Excellence (NICE) - the body that provides guidance on the use of new drugs - said that people coming off the drugs should be offered "structured advice and follow-up support" to help prevent weight gain. This includes being monitored by the NHS for at least a year after completing treatment and support to help build "long-term behavioural habits, use self-monitoring tools, and draw on wider support - from online communities to family-led interventions and local activities". Shortages for diabetics Perhaps a bigger conversation than side effects for individuals is around the impact on people who rely on these treatments, now they've exploded in popularity as a weight loss quick-fix. While intended for diabetics, Ozempic and Mounjaro are prescribed "off-label" in the US to people wanting to shed weight. The drugs faced widespread shortage last year, with reports of diabetics having to drive from pharmacy to pharmacy in search of stock because of the high demand. Links to cancer prevention Research has suggested weight loss jabs, officially GLP-1 receptor agonists, could almost halve the risk of obesity-related cancers. The study, published in the journal eClinicalMedicine, was presented at the European Congress on Obesity in Malaga. It found that there were similar rates of obesity -related cancer among patients treated with the injections and those given weight loss, or bariatric, surgery. Dr Yael Wolff Sagy, the study's co-lead author from Clalit Health Services in Tel-Aviv, Israel, said a "direct effect" of the injections was that they were found "to be 41% more effective at preventing obesity-related cancer". "We do not yet fully understand how GLP-1s work," she said. "But this study adds to the growing evidence showing that weight loss alone cannot completely account for the metabolic, anti-cancer, and many other benefits that these medications provide." Co-lead Professor Dror Dicker, from Hasharon Hospital, Rabin Medical Centre in Israel, suggested the protective effects of the drugs "likely arise from multiple mechanisms, including reducing inflammation". He added further research was needed "to make sure that these drugs do not increase the risk for non-obesity-related cancers". Being overweight or obese is the second biggest cause of cancer in the UK, causing more than one in 20 cancer cases, according to the NHS. Are they available in the UK? An estimated 1.5 million people are taking weight loss jabs in the UK, the vast majority of whom pay for them privately. Ozempic is available in the UK for type 2 diabetes patients with a prescription. Wegovy and Mounjaro is available to NHS patients, but only through specialist weight management services. Over the next three years, around 240,000 people with the "greatest need" are expected to receive Mounjaro through the NHS. However, Sky News research into Wegovy and Mounjaro shows delays in the rollout of both weight loss jabs.
